血液系统恶性肿瘤疾病风险分层系统的开发与验证:EBMT登记组回顾性队列研究
该研究基于EBMT登记组47 265例接受异基因造血干细胞移植的成人患者,开发并验证了涵盖55种组织学与缓解状态组合的疾病风险分层系统(DRSS)。DRSS将患者分为五个风险组,死亡风险随分组递增,并在外部验证队列中区分出四个风险组。DRSS可对既往DRI判定的中间风险患者进行更精细再分层。
要点
- DRSS基于组织学、遗传特征和治疗反应,将移植患者分为五个递增死亡风险组。
- 在外部验证队列中,DRSS区分出四个风险组,风险比随分组升高。
核心结论
- DRSS是一种新型风险分层工具,纳入组织学、遗传特征和治疗反应相关疾病特征。
- 该模型可作为未来研究的基准,并促进异质性队列研究的解读与分析。
研究设计与样本
- 回顾性队列研究,纳入EBMT登记组47 265例成人患者,移植时间为2012年1月1日至2016年12月31日。
- 涵盖急性白血病、淋巴瘤、多发性骨髓瘤、骨髓增殖性和骨髓增生异常性疾病共55种组织学与缓解状态组合。
- EBMT患者分为推导队列(n=25 534)、调优队列(n=18 365)和地理验证队列(n=3366)。
- 独立美国单中心外部验证队列纳入660例患者,移植时间为2010年1月1日至2015年12月31日。
主要发现
- 在所有队列中,既往预后系统DRI将64%至65%的患者归为中间风险。
- 在调优队列与内部地理验证队列合并的14 041例患者亚组分析中,DRSS将DRI中间风险患者再分层为:低风险855例(6%)、中间-1风险7111例(51%)、中间-2风险5700例(41%)、高风险或极高风险375例(3%)。
临床怎么用
- DRSS可用于接受异基因造血干细胞移植的血液系统恶性肿瘤患者的疾病风险分层。
- 对于DRI判定的中间风险患者,DRSS可提供更精细的预后分组以辅助临床决策。
局限性
- 本研究为回顾性队列研究。
- 外部验证来自单中心美国队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diagnosis and remission status at the time of allogeneic haematopoietic stem-cell transplantation (HSCT) are the principal determinants of overall survival following transplantation. We sought to develop a contemporary disease-risk stratification system (DRSS) that accounts for heterogeneous transplantation indications. METHODS: In this retrospective cohort study we included 55 histology and remission status combinations across haematological malignancies, including acute leukaemia, lymphoma, multiple myeloma, and myeloproliferative and myelodysplastic disorders. A total of 47 265 adult patients (aged ≥18 years) who received an allogeneic HSCT between Jan 1, 2012, and Dec 31, 2016, and were reported to the European Society for Blood and Marrow Transplantation registry were included. We divided EBMT patients into derivation (n=25 534), tuning (n=18 365), and geographical validation (n=3366) cohorts. Disease combinations were ranked in a multivariable Cox regression for overall survival in the derivation cohort, cutoff for risk groups were evaluated for the tuning cohort, and the selected system was tested on the geographical validation cohort. An independent single-centre US cohort of 660 patients transplanted between Jan 1, 2010, and Dec 31, 2015 was used to externally validate the results. FINDINGS: The DRSS model stratified patients in the derivation cohort (median follow-up was 2·1 years [IQR 1·0-3·2]) into five risk groups with increasing mortality risk: low risk (reference group), intermediate-1 (hazard ratio for overall survival 1·26 [95% CI 1·17-1·36], p<0·0001), intermediate-2 (1·53 [1·42-1·66], p<0·0001), high (2·03 [1·86-2·22], p<0·0001), and very high (2·87 [2·63-3·13], p<0·0001). DRSS levels were also associated with a stepwise increase in risk across the tuning and geographical validation cohort. In the external validation cohort (median follow-up was 5·7 years [IQR 4·5-7·1]), the DRSS scheme separated patients into 4 risk groups associated with increasing risk of mortality: intermediate-2 risk (hazard ratio [HR] 1·34 [95% CI 1·04-1·74], p=0·025), high risk (HR 2·03 [95% CI 1·39-2·95], p=0·00023) and very-high risk (HR 2·26 [95% CI 1·62-3·15], p<0·0001) patients compared with the low risk and intermediate-1 risk group (reference group). Across all cohorts, between 64% and 65% of patients were categorised as having intermediate-risk disease by a previous prognostic system (ie, the disease-risk index [DRI]). The DRSS reclassified these intermediate-risk DRI patients, with 855 (6%) low risk, 7111 (51%) intermediate-1 risk, 5700 (41%) intermediate-2 risk, and 375 (3%) high risk or very high risk of 14 041 patients in a subanalysis combining the tuning and internal geographic validation cohorts. The DRI projected 2-year overall survival was 62·1% (95% CI 61·2-62·9) for these 14 041 patients, while the DRSS reclassified them into finer prognostic groups with overall survival ranging from 45·7% (37·4-54·0; very high risk patients) to 73·1% (70·1-76·2; low risk patients). INTERPRETATION: The DRSS is a novel risk stratification tool including disease features related to histology, genetic profile, and treatment response. The model should serve as a benchmark for future studies. This system facilitates the interpretation and analysis of studies with heterogeneous cohorts, promoting trial-design with more inclusive populations. FUNDING: The Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University.
引用
- Shouval R, Fein JA, Labopin M, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021. PMID: 33636142. doi:10.1016/S2352-3026(20)30394-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。